Barclays PLC Relmada Therapeutics, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 145,999 shares of RLMD stock, worth $39,419. This represents 0.0% of its overall portfolio holdings.

Number of Shares

145,999

Previous 145,999 -0.0%

Holding current value

$39,419

Previous $473,000 83.93%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	BUY	$2.22 - $3.54 $291,177 - $464,309	131,161 Added 883.95%	145,999 $359,000
Q1 2023 May 04, 2023	BUY	$2.24 - $4.76 $12,120 - $25,756	5,411 Added 57.4%	14,838 $33,000
Q4 2022 Feb 13, 2023	BUY	$2.17 - $35.84 $5,047 - $83,363	2,326 Added 32.76%	9,427 $33,000
Q3 2022 Nov 03, 2022	SELL	$18.3 - $37.02 $175,643 - $355,317	-9,598 Reduced 57.48%	7,101 $263,000
Q2 2022 Aug 12, 2022	BUY	$16.5 - $30.34 $247,483 - $455,069	14,999 Added 882.29%	16,699 $317,000
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $28,423 - $45,883	1,700 New	1,700 $46,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

8.32M

Call Options Held

364K

Put Options Held

46.5K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $7.72M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account